Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Zillow Group Inc Class C (Z) Price & Performance

Charles River Laboratories Intl. IncTrade
Zillow Group Inc Class CTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Zillow Group Inc Class C — how do they compare? Charles River Laboratories Intl. Inc trades at $281.43 (market cap $13.46B), while Zillow Group Inc Class C trades at $34.1 (market cap $7.68B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.

CRLZ
Market Cap
$13.46B$7.68B
Sector
HealthMedia
52-Week High
$282.00$90.35
52-Week Low
$145.57$29.41
Enterprise Value
$16.30B$7.56B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Zillow Group Inc Class C

Zillow Group (Z) trades at $33.10, down 1.93% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is solid, rising to $2.58B in 2025, but profitability remains thin with a net margin of 1.96%. The stock faces headwinds from a securities class action lawsuit and a challenging real estate market, though analyst consensus points to significant upside with a $52 price target.

The outlook is cautious due to legal risks and weak near-term profitability, but long-term monetization potential and analyst optimism suggest opportunity if execution improves. Key risks include litigation outcomes and market volatility, while institutional sentiment leans neutral with a 50% hold rating.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Zillow Group Inc Class C

Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.

Read more on Z